Metrovacesa S.A.

BME:MVC Stok Raporu

Piyasa değeri: €1.6b

Metrovacesa Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 4/6

Metrovacesa yıllık ortalama 54.1% oranında kazançlarını artırırken, Real Estate sektöründe kazançlar growing at 17.5% annual. Gelirler growing yılda ortalama 16.4% oranında artmaktadır. Metrovacesa'in özkaynak karlılığı 4% ve net marjı 8%'dir.

Anahtar bilgiler

54.14%

Kazanç büyüme oranı

61.06%

EPS büyüme oranı

Real Estate Sektör Büyümesi17.43%
Gelir büyüme oranı16.39%
Özkaynak getirisi4.02%
Net Marj8.03%
Sonraki Kazanç Güncellemesi22 Jul 2026

Yakın geçmiş performans güncellemeleri

Analiz Makalesi Feb 26

Metrovacesa's (BME:MVC) Performance Is Even Better Than Its Earnings Suggest

Even though Metrovacesa S.A.'s ( BME:MVC ) recent earnings release was robust, the market didn't seem to notice. We...
Analiz Makalesi Aug 01

We Think Metrovacesa's (BME:MVC) Profit Is Only A Baseline For What They Can Achieve

The subdued stock price reaction suggests that Metrovacesa S.A.'s ( BME:MVC ) strong earnings didn't offer any...

Recent updates

Anlatı Güncellemesi Jun 11

MVC: Slightly Lower Required Return And Rich P/E Will Shape Future Upside

Analysts now cite a slightly higher fair value per share for Metrovacesa, lifting their price target from €11.17 to €11.28. This revision is supported by small refinements to assumptions for the discount rate, revenue growth, profit margin and future P/E.
Anlatı Güncellemesi May 28

MVC: Slightly Lower Required Return And Rich P/E Will Shape Future Upside

Analysts have nudged their fair value estimate for Metrovacesa to €11.17 from €10.81, citing updated assumptions around the discount rate and future P/E, while keeping revenue growth and profit margin expectations broadly unchanged. Valuation Changes Fair Value: €11.17, up slightly from €10.81.
Anlatı Güncellemesi May 02

MVC: Slightly Higher Required Return And Rich P/E Will Constrain Future Upside

Analysts have kept their average price target for Metrovacesa broadly steady around €10.81, citing only slight shifts in discount rate, profit margin assumptions and future P/E expectations rather than any major change in the investment case. Valuation Changes Fair Value: The €10.81 fair value estimate is unchanged, indicating a stable central valuation point in the model.
Anlatı Güncellemesi Apr 17

MVC: Higher Required Return And Rich P/E Will Pressure Future Returns

Analysts have kept their price target for Metrovacesa broadly unchanged at around €10.81 per share. The latest revisions reflect only very small model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any shift in their core view.
Anlatı Güncellemesi Apr 03

MVC: Stable Assumptions And Discount Rate Tweaks Will Guide Future Returns

Analysts keep their Metrovacesa price target steady at €10.81, indicating largely unchanged assumptions on fair value, growth, margins, and future P/E, with only minor adjustments to discount rates and long-term expectations. Valuation Changes Fair Value: €10.81 per share is unchanged, suggesting the core view of what the stock is worth on a fundamental basis remains the same.
Anlatı Güncellemesi Mar 20

MVC: Dividend Outlook And Revised Assumptions Will Shape Future Return Balance

Analysts now set their fair value estimate for Metrovacesa at €10.81 per share, up from €10.63. This reflects updated assumptions around the discount rate, revenue growth, profit margin and future P/E.
Anlatı Güncellemesi Mar 06

MVC: Lower Growth Assumptions And Elevated P/E Will Sustain Bearish View

Analysts have modestly lowered their price target on Metrovacesa to €9.30, citing updated assumptions for revenue growth, profit margins and the future P/E multiple, while keeping their fair value estimate unchanged at €9.30. Valuation Changes Fair Value: The fair value estimate is unchanged at €9.30 per share, indicating no revision to the overall valuation outcome.
Anlatı Güncellemesi Feb 20

MVC: Dividend Outlook And Updated Assumptions Will Shape Future Return Balance

Analysts have slightly trimmed their fair value estimate for Metrovacesa from €10.83 to €10.63, citing updated assumptions around discount rates, expected revenue growth, margins and future P/E levels. Valuation Changes Fair Value: Trimmed slightly from €10.83 to €10.63 per share.
Anlatı Güncellemesi Feb 06

MVC: Lower Discount Rate And High P/E Will Sustain Bearish View

Analysts have slightly raised their price target on Metrovacesa, citing updated assumptions for the discount rate, revenue growth, profit margins and future P/E, which together indicate a modestly higher fair value per share in euro terms. Valuation Changes Fair Value: unchanged at €9.30 per share.
Anlatı Güncellemesi Jan 23

MVC: Dividend Reserve Plans And P/E Revisions Will Guide Cautious Outlook

Analysts have maintained their Metrovacesa fair value target at €9.30, citing a combination of updated assumptions that include slightly lower discount rates, higher revenue growth expectations, softer profit margins and a higher future P/E multiple in their latest models. What's in the News Metrovacesa has scheduled a Special and Extraordinary Shareholders Meeting for November 25, 2025, at 13:00 Central European Standard Time in Madrid, Spain (Key Developments).
Anlatı Güncellemesi Jan 08

MVC: Dividend Proposal At Extraordinary Meeting Will Support Bullish Thesis

Analysts have revised their price target on Metrovacesa from €11.80 to €13.10, citing updated assumptions around discount rates, revenue growth, profit margins, and the future P/E multiple. What's in the News Metrovacesa has scheduled a Special and Extraordinary Shareholders Meeting for November 25, 2025, at 13:00 Central European Standard Time in Madrid, Spain (calle principe de vergara 187, plaza de rodrigo uria, madrid) (Key Developments) The meeting agenda includes a proposal to discuss the distribution of dividends from freely distributable reserves, which may be relevant if you are focusing on potential cash returns to shareholders (Key Developments) The notice also refers to discussion of other matters at the meeting, indicating that additional shareholder topics could be addressed beyond dividends (Key Developments) Valuation Changes Fair Value Estimate was revised from €11.80 to €13.10, indicating a higher assessed value per share.
Anlatı Güncellemesi Dec 24

MVC: Dividend Reserve Plans Will Shape A Cautious Medium-Term Outlook

Analysts have raised their price target on Metrovacesa from €6.50 to €9.30, citing higher expected revenue growth, improved profit margins, and a modestly richer future P/E multiple, despite a slightly higher discount rate. What's in the News Metrovacesa has called a special shareholders meeting for November 25, 2025, at 13:00 CET in Madrid to address key corporate matters.
Analiz Makalesi Dec 20

Metrovacesa S.A. (BME:MVC) Shares Could Be 23% Below Their Intrinsic Value Estimate

Key Insights Metrovacesa's estimated fair value is €11.52 based on 2 Stage Free Cash Flow to Equity Current share price...
Anlatı Güncellemesi Dec 10

MVC: Dividend Decision And Revised Outlook Will Shape Balanced Return Prospects

Analysts have raised their price target on Metrovacesa from €9.81 to €10.83, citing a higher long term fair value despite moderating assumptions for revenue growth, profit margins and future earnings multiples. What's in the News Metrovacesa has scheduled a special and extraordinary shareholders meeting for November 25, 2025, at 13:00 Central European Standard Time in Madrid, Spain (Key Developments) The main agenda item for the upcoming meeting is the potential distribution of dividends from freely distributable reserves, which could affect shareholder returns policy (Key Developments) Shareholders will also address other unspecified matters at the meeting, leaving scope for additional corporate or capital structure decisions (Key Developments) Valuation Changes Fair Value: raised slightly from €9.81 to €10.83 per share, reflecting a modest uplift in long term valuation.
Analiz Makalesi Oct 02

Should You Think About Buying Metrovacesa S.A. (BME:MVC) Now?

Metrovacesa S.A. ( BME:MVC ), is not the largest company out there, but it had a relatively subdued couple of weeks in...
Analiz Makalesi Jul 25

Calculating The Fair Value Of Metrovacesa S.A. (BME:MVC)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Metrovacesa fair value estimate is €12.58 Metrovacesa's €10.15...
Analiz Makalesi May 04

Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analiz Makalesi Apr 12

Are Investors Undervaluing Metrovacesa S.A. (BME:MVC) By 40%?

Key Insights The projected fair value for Metrovacesa is €16.96 based on 2 Stage Free Cash Flow to Equity Metrovacesa...
Analiz Makalesi Feb 26

Metrovacesa's (BME:MVC) Performance Is Even Better Than Its Earnings Suggest

Even though Metrovacesa S.A.'s ( BME:MVC ) recent earnings release was robust, the market didn't seem to notice. We...
User avatar
Yeni Anlatı Feb 19

Will Leverage Undersupplied Spanish Housing Market For Future Opportunities

High presales coverage allows focus on margin maximization, boosting future net margins amid an undersupplied market.
Analiz Makalesi Feb 07

Is It Time To Consider Buying Metrovacesa S.A. (BME:MVC)?

While Metrovacesa S.A. ( BME:MVC ) might not have the largest market cap around , it maintained its current share price...
Analiz Makalesi Dec 13

An Intrinsic Calculation For Metrovacesa S.A. (BME:MVC) Suggests It's 44% Undervalued

Key Insights Metrovacesa's estimated fair value is €16.39 based on 2 Stage Free Cash Flow to Equity Metrovacesa's €9.13...
Analiz Makalesi Sep 12

Estimating The Fair Value Of Metrovacesa S.A. (BME:MVC)

Key Insights The projected fair value for Metrovacesa is €9.93 based on 2 Stage Free Cash Flow to Equity Metrovacesa's...
Analiz Makalesi Aug 01

We Think Metrovacesa's (BME:MVC) Profit Is Only A Baseline For What They Can Achieve

The subdued stock price reaction suggests that Metrovacesa S.A.'s ( BME:MVC ) strong earnings didn't offer any...
Analiz Makalesi Jul 17

Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?

While Metrovacesa S.A. ( BME:MVC ) might not have the largest market cap around , it saw significant share price...
Analiz Makalesi May 28

A Look At The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Metrovacesa fair value estimate is €9.31 Current share price...
Analiz Makalesi May 01

We Think Metrovacesa (BME:MVC) Can Stay On Top Of Its Debt

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analiz Makalesi Mar 27

Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?

While Metrovacesa S.A. ( BME:MVC ) might not have the largest market cap around , it received a lot of attention from a...
Analiz Makalesi Feb 12

A Look At The Fair Value Of Metrovacesa S.A. (BME:MVC)

Key Insights The projected fair value for Metrovacesa is €9.08 based on 2 Stage Free Cash Flow to Equity Current share...
Analiz Makalesi Nov 05

Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analiz Makalesi Jul 05

These 4 Measures Indicate That Metrovacesa (BME:MVC) Is Using Debt Extensively

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analiz Makalesi May 21

Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?

While Metrovacesa S.A. ( BME:MVC ) might not be the most widely known stock at the moment, it saw significant share...
Analiz Makalesi Apr 19

Estimating The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Metrovacesa fair value estimate is €7.36 Current share price...
Analiz Makalesi Dec 02

Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analiz Makalesi Sep 23

Is It Too Late To Consider Buying Metrovacesa S.A. (BME:MVC)?

While Metrovacesa S.A. ( BME:MVC ) might not be the most widely known stock at the moment, it received a lot of...
Analiz Makalesi May 19

Estimating The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)

Does the May share price for Metrovacesa S.A. ( BME:MVC ) reflect what it's really worth? Today, we will estimate the...
Analiz Makalesi Mar 05

Metrovacesa's (BME:MVC) Strong Earnings Are Of Good Quality

Metrovacesa S.A. ( BME:MVC ) just reported healthy earnings but the stock price didn't move much. We think that...
Analiz Makalesi Feb 16

Would Metrovacesa (BME:MVC) Be Better Off With Less Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Analiz Makalesi Oct 05

Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analiz Makalesi Jul 02

Is Metrovacesa S.A. (BME:MVC) Worth €6.7 Based On Its Intrinsic Value?

Today we will run through one way of estimating the intrinsic value of Metrovacesa S.A. ( BME:MVC ) by projecting its...
Analiz Makalesi May 06

Is Metrovacesa (BME:MVC) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analiz Makalesi Apr 06

Is Metrovacesa S.A. (BME:MVC) A Strong Dividend Stock?

Is Metrovacesa S.A. ( BME:MVC ) a good dividend stock? How can we tell? Dividend paying companies with growing earnings...
Analiz Makalesi Mar 15

Metrovacesa (BME:MVC) Share Prices Have Dropped 51% In The Last Three Years

Metrovacesa S.A. ( BME:MVC ) shareholders should be happy to see the share price up 12% in the last month. But that...
Analiz Makalesi Feb 16

Loss-Making Metrovacesa S.A. (BME:MVC) Set To Breakeven

We feel now is a pretty good time to analyse Metrovacesa S.A.'s ( BME:MVC ) business as it appears the company may be...
Analiz Makalesi Jan 26

When Should You Buy Metrovacesa S.A. (BME:MVC)?

Metrovacesa S.A. ( BME:MVC ), might not be a large cap stock, but it led the BME gainers with a relatively large price...
Analiz Makalesi Jan 05

A Look At The Fair Value Of Metrovacesa S.A. (BME:MVC)

In this article we are going to estimate the intrinsic value of Metrovacesa S.A. ( BME:MVC ) by taking the expected...
Analiz Makalesi Dec 14

If You Had Bought Metrovacesa's (BME:MVC) Shares A Year Ago You Would Be Down 24%

Metrovacesa S.A. ( BME:MVC ) shareholders should be happy to see the share price up 11% in the last month. But that...

Gelir ve Gider Dağılımı

Metrovacesa nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

BME:MVC Gelir, gider ve kazançlar (EUR Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
31 Dec 2570857510
30 Sep 2563227510
30 Jun 25555-3510
31 Mar 256046520
31 Dec 2465316540
30 Sep 2465117530
30 Jun 2464918530
31 Mar 24616-15530
31 Dec 23581-21520
30 Sep 23535-68510
30 Jun 23430-71520
31 Mar 23454-38510
31 Dec 22516-23510
30 Sep 2252925570
30 Jun 2257233560
31 Mar 2257531550
31 Dec 2151218530
30 Sep 21413-71470
30 Jun 21231-90400
31 Mar 21138-160340
31 Dec 20140-164340
30 Sep 20164-87340
30 Jun 20180-87340
31 Mar 20214-6350
31 Dec 19161-4340
30 Sep 192060330
30 Jun 192205310
31 Mar 19211-11280
31 Dec 18190-9290
30 Sep 18103-14230
30 Jun 1870-31260
31 Mar 1834-34180
31 Dec 1728-39150
30 Sep 1729-55110
31 Dec 1621-2170
31 Dec 15366480

Kaliteli Kazançlar: MVC büyük bir tek seferlik zarar ile €36.9M, 31st December, 2025 tarihine ait son 12 aylık mali sonuçları etkiliyor.

Büyüyen Kar Marjı: MVC 'nin mevcut net kar marjları (8%) geçen yılın (2.4%) sinden daha yüksektir.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: MVC son 5 yılda karlı hale geldi ve kazançlarını yıllık 54.1% oranında artırdı.

Büyüme Hızlandırma: MVC 'un son bir yıldaki kazanç büyümesi ( 257.9% ) 5 yıllık ortalamasını (yıllık 54.1% ) aşıyor.

Kazançlar vs. Sektör: MVC geçen yılki kazanç büyümesi ( 257.9% ) Real Estate sektörünün 73.5% değerini aştı.


Özkaynak Getirisi

Yüksek ROE: MVC 'nin Özsermaye Getirisi ( 4% ) düşük olarak değerlendiriliyor.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/06/15 12:35
Gün Sonu Hisse Fiyatı2026/06/15 00:00
Kazançlar2025/12/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Metrovacesa S.A. 22 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Ignacio RomeroBanco de Sabadell. S.A.
null nullBanco de Sabadell. S.A.
Mariano Miguel HidalgoBanco Santander